Table E3.
Comorbidities by valve type in unmatched patients who underwent mitral valve replacement for endocarditis
| Characteristic | All patients N = 4207 | B-MVR n = 3126 | M-MVR n = 1081 | P value∗ |
|---|---|---|---|---|
| Elixhauser score | 19 (9, 30) | 19 (9, 30) | 19 (8, 29) | .19 |
| Congestive heart failure | 2191 (52.1%) | 1649 (52.8%) | 541 (50.1%) | .28 |
| Arrhythmia | 2427 (57.7%) | 1831 (58.6%) | 596 (55.1%) | .17 |
| Valve disease | 2997 (71.3%) | 2206 (70.6%) | 791 (73.2%) | .30 |
| Pulmonary circulation disorder | 942 (22.4%) | 714 (22.8%) | 229 (21.2%) | .44 |
| Peripheral vascular disease | 308 (7.3%) | 253 (8.1%) | 55 (5.1%) | .03 |
| Hypertension | 2429 (57.8%) | 1836 (58.7%) | 594 (54.9%) | .15 |
| COPD | 805 (19.1%) | 629 (20.1%) | 176 (16.3%) | .06 |
| Diabetes mellitus | 934 (22.2%) | 760 (24.3%) | 174 (16.1%) | <.01 |
| Renal failure | 1102 (26.2%) | 846 (27.1%) | 256 (23.7%) | .13 |
| Liver disease | 613 (14.6%) | 460 (14.7%) | 153 (14.1%) | .76 |
| Coagulopathy | 1506 (35.8%) | 1107 (35.4%) | 399 (37.0%) | .54 |
| Electrolyte disorder | 2623 (62.4%) | 1948 (62.3%) | 674 (62.4%) | .98 |
| Deficiency anemia | 423 (10.0%) | 306 (9.8%) | 116 (10.7%) | .54 |
| Alcohol abuse | 298 (7.1%) | 219 (7.0%) | 79 (7.3%) | .84 |
| Substance abuse | 927 (22.0%) | 670 (21.4%) | 257 (23.8%) | .28 |
| Stroke | 976 (23.1%) | 762 (24.4%) | 214 (19.8%) | .59 |
Data presented as n (%) or median (interquartile range). B-MVR, Bioprosthetic mitral valve replacement; M-MVR, mechanical mitral valve replacement; COPD, chronic obstructive pulmonary disease.
∗
Chi-square test with Rao & Scott's second-order correction.